| Item Type | Name |
|
Academic Article
|
High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignancies.
|
|
Academic Article
|
Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin's lymphoma: effect of the specific high-dose chemotherapy regimen on outcome.
|
|
Concept
|
Melphalan
|
|
Academic Article
|
Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT.
|
|
Academic Article
|
Feasibility of autologous hematopoietic stem cell transplant in patients aged =70 years with multiple myeloma.
|
|
Academic Article
|
Autologous stem cell transplantation is safe and feasible in elderly patients with multiple myeloma.
|
|
Academic Article
|
Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome.
|
|
Academic Article
|
Moderate renal function impairment does not affect outcomes of reduced-intensity conditioning with fludarabine and melphalan for allogeneic hematopoietic stem cell transplantation.
|
|
Academic Article
|
Intravenous BU plus Mel: an effective, chemotherapy-only transplant conditioning regimen in patients with ALL.
|
|
Academic Article
|
Long-term outcome of reduced-intensity allogeneic hematopoietic SCT in patients with AML in CR.
|
|
Academic Article
|
A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid.
|
|
Academic Article
|
Fifty years of melphalan use in hematopoietic stem cell?transplantation.
|
|
Academic Article
|
Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan.
|
|
Academic Article
|
Deletion of the short arm of chromosome 1 (del 1p) is a strong predictor of poor outcome in myeloma patients undergoing an autotransplant.
|
|
Academic Article
|
A randomized phase II trial of fludarabine/melphalan 100 versus fludarabine/melphalan 140 followed by allogeneic hematopoietic stem cell transplantation for patients with multiple myeloma.
|
|
Academic Article
|
Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience.
|
|
Academic Article
|
Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trial.
|
|
Academic Article
|
Phase II trial of high-dose topotecan, melphalan and CY with autologous stem cell support for multiple myeloma.
|
|
Academic Article
|
Fludarabine, melphalan, thiotepa and anti-thymocyte globulin conditioning for unrelated cord blood transplant.
|
|
Academic Article
|
Using joint utilities of the times to response and toxicity to adaptively optimize schedule-dose regimes.
|
|
Academic Article
|
Intravenous busulfan plus melphalan is a highly effective, well-tolerated preparative regimen for autologous stem cell transplantation in patients with advanced lymphoid malignancies.
|
|
Academic Article
|
Durable responses with autologous hematopoietic SCT in patients with POEMS syndrome.
|
|
Academic Article
|
Short-term cardiac toxicity of autologous hematopoietic stem cell transplant for multiple myeloma.
|
|
Academic Article
|
Phase I/II trial of lenalidomide and high-dose melphalan with autologous stem cell transplantation for relapsed myeloma.
|
|
Academic Article
|
High-dose therapy with auto-SCT is feasible in high-risk cardiac amyloidosis.
|
|
Academic Article
|
Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas.
|
|
Academic Article
|
Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas
|
|
Academic Article
|
Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma.
|
|
Academic Article
|
A randomized phase II study of standard-dose versus high-dose rituximab with BEAM in autologous stem cell transplantation for relapsed aggressive B-cell non-hodgkin lymphomas: long term results.
|
|
Academic Article
|
High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalan.
|
|
Academic Article
|
Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma.
|
|
Academic Article
|
Amifostine reduces gastro-intestinal toxicity after autologous transplantation for multiple myeloma.
|
|
Academic Article
|
Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma.
|
|
Academic Article
|
Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial.
|
|
Academic Article
|
Melphalan-based autologous transplant in octogenarian multiple myeloma patients.
|
|
Academic Article
|
Impact of Donor Type and Melphalan Dose on Allogeneic Transplantation Outcomes for Patients with Lymphoma.
|
|
Academic Article
|
Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial.
|
|
Academic Article
|
Outcomes of autologous stem cell transplantation in Waldenstr?m's macroglobulinemia.
|
|
Academic Article
|
Panobinostat and venetoclax enhance the cytotoxicity of gemcitabine, busulfan, and melphalan in multiple myeloma cells.
|
|
Academic Article
|
Age no bar: A CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma.
|
|
Academic Article
|
Busulfan and melphalan conditioning is superior to melphalan alone in autologous stem cell transplantation for high-risk MM.
|
|
Academic Article
|
Outcomes of upfront autologous hematopoietic cell transplantation in patients with multiple myeloma who are 75 years old or older.
|
|
Academic Article
|
Melphalan dose intensity for autologous stem cell transplantation in multiple myeloma.
|
|
Academic Article
|
Stability of Captisol-enabled versus propylene glycol-based melphalan at room temperature and after refrigeration.
|
|
Academic Article
|
Impact of second primary malignancy post-autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis.
|
|
Academic Article
|
Clinicopathologic Features of Therapy-Related Myeloid Neoplasms in Patients with Myeloma in the Era of Novel Therapies.
|
|
Academic Article
|
High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma.
|
|
Academic Article
|
Outcomes of t(11;14) light chain (AL) amyloidosis after autologous stem cell transplantation: benchmark for new therapies.
|
|
Academic Article
|
Safety and efficacy of a new high-dose regimen of panobinostat, gemcitabine, busulfan, and melphalan for 1st or 2nd salvage ASCT for refractory/relapsed or high-risk myeloma: Matched-pair comparisons with concurrent control cohorts.
|